As of Feb 27
| -0.04 / -0.10%|
The 2 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 49.25, with a high estimate of 53.00 and a low estimate of 45.50. The median estimate represents a +23.37% increase from the last price of 39.92.
The current consensus among 2 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.